{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:21Z","timestamp":1792636701605,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12185-016-2106-z","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T08:52:05Z","timestamp":1475657525000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Zhi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-xing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-peng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"issue":"5","key":"2106_CR1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00277-011-1163-x","volume":"90","author":"JC Jaime-P\u00e9rez","year":"2011","unstructured":"Jaime-P\u00e9rez JC, Colunga-Pedraza PR, G\u00f3mez-Ram\u00edrez CD, Guti\u00e9rrez-Aguirre CH, Cant\u00fa-Rodr\u00edguez OG, Tar\u00edn-Arzaga LC, et al. Danazol as first-line therapy for aplastic anemia [J]. Ann Hematol. 2011;90(5):523\u20137.","journal-title":"Ann Hematol"},{"issue":"12","key":"2106_CR2","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","volume":"99","author":"N Yoshida","year":"2014","unstructured":"Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor vs immunosuppressive therapy [J]. Haematologica. 2014;99(12):1784\u201391.","journal-title":"Haematologica"},{"issue":"2","key":"2106_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12185-015-1818-9","volume":"102","author":"M Wang","year":"2015","unstructured":"Wang M, Li X, Shi J, Shao Y, Ge M, Huang J, et al. Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia [J]. Int J Hematol. 2015;102(2):149\u201356.","journal-title":"Int J Hematol"},{"issue":"5","key":"2106_CR4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","volume":"50","author":"I Esteves","year":"2015","unstructured":"Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study [J]. Bone Marrow Transplant. 2015;50(5):685\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2106_CR5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12185-013-1425-6","volume":"98","author":"Y Fu","year":"2013","unstructured":"Fu Y, Wang Q, Zhou J, Liu S, Fang B, Wei X, et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem\/stroma cells for young patients with refractory severe aplastic anemia [J]. Int J Hematol. 2013;98(6):658\u201363.","journal-title":"Int J Hematol"},{"issue":"3","key":"2106_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00005-012-0174-1","volume":"60","author":"D Szpecht","year":"2012","unstructured":"Szpecht D, Gorczy\u0144ska E, Ka\u0142wak K, Owoc-Lempach J, Choma M, Styczy\u0144ski J, et al. Matched sibling vs matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia:experience of the polish pediatric group for hematopoietic stem cell transplantation [J]. Arch Immunol Ther Exp (Warsz). 2012;60(3):225\u201333.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"2","key":"2106_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12185-013-1263-6","volume":"97","author":"S Wang","year":"2013","unstructured":"Wang S, Chen Y, Zou Y, Zheng Y, Zhu X. The progression risk factors of children with transfusion-independent non-severe aplastic anemia [J]. Int J Hematol. 2013;97(2):210\u20135.","journal-title":"Int J Hematol"},{"issue":"4","key":"2106_CR8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3857\/roj.2012.30.4.165","volume":"30","author":"YH Lee","year":"2012","unstructured":"Lee YH, Kim JY, Choi BO, Ryu MR, Chung SM. Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia [J]. Radiat Oncol J. 2012;30(4):165\u201372.","journal-title":"Radiat Oncol J"},{"issue":"6","key":"2106_CR9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-3046.2011.01542.x","volume":"15","author":"A Pillai","year":"2011","unstructured":"Pillai A, Hartford C, Wang C, Pei D, Yang J, Srinivasan A, et al. Favorable preliminary results using TLI\/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia [J]. Pediatr Transplant. 2011;15(6):628\u201334.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"2106_CR10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ajh.23392","volume":"88","author":"Y Kanda","year":"2013","unstructured":"Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation [J]. Am J Hematol. 2013;88(4):294\u2013300.","journal-title":"Am J Hematol"},{"issue":"5","key":"2106_CR11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2016.01.027","volume":"22","author":"CM Vajdic","year":"2016","unstructured":"Vajdic CM, Mayson E, Dodds AJ, O\u2019Brien T, Wilcox L, Nivison-Smith I, et al. Second cancer risk and late mortality in adult Australians receiving allogeneic hematopoietic stem cell transplantation: a population-based cohort study [J]. Biol Blood Marrow Transplant. 2016;22(5):949\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2106_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000357108","volume":"132","author":"S Vel\u00e1zquez-S\u00e1nchez-de-Cima","year":"2014","unstructured":"Vel\u00e1zquez-S\u00e1nchez-de-Cima S, Zamora-Ortiz G, Hern\u00e1ndez-Reyes J, Rosales-Dur\u00f3n AD, Gonz\u00e1lez-Ram\u00edrez MP, Martag\u00f3n-Herrera NA, et al. Oral vs intravenous fludarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation [J]. Acta Haematol. 2014;132(1):125\u20138.","journal-title":"Acta Haematol"},{"issue":"10","key":"2106_CR13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.bbmt.2015.06.015","volume":"21","author":"S Hutspardol","year":"2015","unstructured":"Hutspardol S, Essa M, Richardson S, Schechter T, Ali M, Krueger J, et al. Significant transplantation-related mortality from respiratory virus infections within the first 100\u00a0days in children after hematopoietic stem cell transplantation [J]. Biol Blood Marrow Transplant. 2015;21(10):1802\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2106_CR14","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse [J]. J Clin Oncology. 2005;23(15):3447\u201354.","journal-title":"J Clin Oncology"},{"issue":"6","key":"2106_CR15","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1537-2995.2011.03457.x","volume":"52","author":"N Worel","year":"2012","unstructured":"Worel N, B\u00f6hm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, et al. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning [J]. Transfusion. 2012;52(6):1348\u201353.","journal-title":"Transfusion"},{"issue":"9","key":"2106_CR16","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/bmt.2014.122","volume":"49","author":"K Fleischhauer","year":"2014","unstructured":"Fleischhauer K, Fernandez-Vi\u00f1a MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1 [J]. Bone Marrow Transplant. 2014;49(9):1176\u201383.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2106_CR17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/bmt.2015.50","volume":"50","author":"SR Jaiswal","year":"2015","unstructured":"Jaiswal SR, Chatterjee S, Mukherjee S, Ray K, Chakrabarti S. Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia [J]. Bone Marrow Transplant. 2015;50(6):873\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2106_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J]. Biol Blood Marrow Transplant. 2008;14(6):641\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2106_CR19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.transci.2010.12.007","volume":"44","author":"C Chun","year":"2011","unstructured":"Chun C, Fang JP, Xue HM, Zhou DH, Huang K, Xu HG, et al. Allogeneic hematopoietic stem cell transplantation for childhood aplastic anemia:prospective trial in China [J]. Transfus Apher Sci. 2011;44(1):41\u20137.","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"2106_CR20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.bbmt.2010.12.715","volume":"17","author":"H Kim","year":"2011","unstructured":"Kim H, Kim BS, Kim DH, Hyun MS, Kim SH, Bae SH, et al. Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia:multivariate and propensity score-matched analysis [J]. Biol Blood Marrow Transplant. 2011;17(9):1289\u201398.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2106_CR21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","volume":"43","author":"H Nakamae","year":"2015","unstructured":"Nakamae H, Koh H, Katayama T, Nishimoto M, Hayashi Y, Nakashima Y, et al. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome [J]. Exp Hematol. 2015;43(11):921\u20139.","journal-title":"Exp Hematol"},{"issue":"3","key":"2106_CR22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jare.2014.11.001","volume":"6","author":"HK Mahmoud","year":"2015","unstructured":"Mahmoud HK, Elhaddad AM, Fahmy OA, Samra MA, Abdelfattah RM, El-Nahass YH, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders [J]. J Adv Res. 2015;6(3):449\u201358.","journal-title":"J Adv Res"},{"issue":"12","key":"2106_CR23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","volume":"18","author":"SO Ciurea","year":"2012","unstructured":"Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation [J]. Biol Blood Marrow Transplant. 2012;18(12):1835\u201344.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2106_CR24","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation [J]. J Clin Oncol. 2013;31(10):1310\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2106_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12185-012-1097-7","volume":"96","author":"K Ikegame","year":"2012","unstructured":"Ikegame K, Kaida K, Yoshihara S, Fujiwara M, Taniguchi K, Kato R, et al. Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients [J]. Int J Hematol. 2012;96(1):101\u20138.","journal-title":"Int J Hematol"},{"issue":"4","key":"2106_CR26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12185-014-1542-x","volume":"99","author":"K Kaida","year":"2014","unstructured":"Kaida K, Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-vs-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning [J]. Int J Hematol. 2014;99(4):463\u201370.","journal-title":"Int J Hematol"},{"issue":"5","key":"2106_CR27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","volume":"121","author":"P Bartolomeo Di","year":"2013","unstructured":"Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies [J]. Blood. 2013;121(5):849\u201357.","journal-title":"Blood"},{"issue":"10","key":"2106_CR28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.bbmt.2012.03.015","volume":"18","author":"H Kim","year":"2012","unstructured":"Kim H, Lee KH, Yoon SS, Sohn SK, Joo YD, Kim SH, et al. Allogeneic hematopoietic stem cell transplant for adults over 40\u00a0years old with acquired aplastic anemia [J]. Biol Blood Marrow Transplant. 2012;18(10):1500\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2106_CR29","first-page":"1359","volume":"22","author":"Z Guo","year":"2014","unstructured":"Guo Z, Chen HR, Liu XD, Lou JX, Yang K, Zhang Y, et al. Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(5):1359\u201364.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"2106_CR30","first-page":"441","volume":"21","author":"Z Guo","year":"2013","unstructured":"Guo Z, Chen HR, Liu XD, Lou JX, Yang K, Zhang Y, et al. Clinical research of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(2):441\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2106-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:41:44Z","timestamp":1718811704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2106-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2106-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}